There's no denying that artificial intelligence (AI) is going to revolutionise the world of business.
However, some businesses stand to benefit more than others. And few more so than Pro Medicus Limited (ASX: PME).
At present, it is known as a health imaging technology stock. But given just how much AI could impact its operations, it probably won't be long until it is known as an ASX AI stock.
Image source: Getty Images
Why is Pro Medicus an ASX AI stock?
The team at Goldman Sachs was running the rule over the company last week and highlighted its enormous opportunity with AI.
But firstly, as a reminder, let's just look at what Pro Medicus actually is today.
It is a leading provider of radiology information systems (RIS), Picture Archiving and Communication Systems (PACS), and advanced visualisation solutions across the world.
Its key offering is the Visage 7 Enterprise Imaging Platform. It provides a fast, clinically rich, and highly scalable growth platform that is deliverable entirely from the cloud or on premise.
This disruptive platform is regarded as the best in its class and has been winning huge long-term contracts from some of the most highly regarded healthcare institutions in the world. This has led to explosive earnings growth over the last decade.
Now, let's get back to what makes this an AI stock. Goldman explained in its note this week, it said:
AI opens an incremental US$620mn TAM today (growing at a +34.7% CAGR) with radiology receiving the majority (c.80%) of recent FDA AI algorithm clearance. We believe PME is well positioned to take share as the incumbent viewing platform across many large, and likely early adopters of new technology.
PME is generating revenue from its Visage breast density AI algorithm (developed via a partnership with Yale) today, and we see the potential value for AI to be significant with adoption driven by improved accuracy and clinical outcomes. We forecast AI to comprise 9% of PME's revenue by FY30E (from <1% in FY25E), with upside if PME achieves faster AI attach penetration, higher price per scan, and a greater proportion of algorithms developed in-house where no royalties are paid to a partner.
Is it a buy?
Goldman thinks Pro Medicus is an AI stock to buy right now.
Last week, it initiated coverage on the company's shares with a buy rating and a $134.00 price target.
This implies a potential upside of approximately 30% for investors over the next 12 months.
